DOTATOC is a specialized term used in the field of medicine, specifically in the domain of nuclear medicine. It refers to a radiopharmaceutical agent that is utilized in diagnostic imaging procedures, particularly in the identification and evaluation of neuroendocrine tumors and their metastases.
DOTATOC is an acronym derived from its chemical structure, which consists of a compound called DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and a peptide sequence known as TOC (tyrosine-octreotide). The DOTA moiety acts as a chelator, enabling the attachment of radioactive isotopes such as gallium-68 or lutetium-177, while the TOC component targets somatostatin receptors on neuroendocrine tumor cells.
The administration of DOTATOC in patients allows for the identification of somatostatin receptor-positive tumors using a positron emission tomography (PET) scan. This technique combines functional and anatomical imaging, providing precise information about the location, size, and metabolic activity of the tumor. DOTATOC has gained popularity in recent years due to its high binding affinity and specificity for somatostatin receptors, making it an effective tool for accurate tumor detection and staging.
The use of DOTATOC contributes to improved diagnosis, treatment planning, and monitoring of patients with neuroendocrine tumors. Its specific action and radioactive properties enable physicians to better understand the extent of disease involvement and tailor appropriate therapeutic strategies.
